Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR) have earned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $36.00.

Several equities analysts have recently issued reports on the stock. BMO Capital Markets reduced their price target on shares of Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a report on Wednesday, February 28th. Wedbush reduced their target price on shares of Xencor from $36.00 to $34.00 and set an “outperform” rating for the company in a research note on Wednesday, February 28th. Piper Sandler restated a “neutral” rating and issued a $24.00 price target (down previously from $37.00) on shares of Xencor in a research note on Wednesday, February 28th. BTIG Research reduced their price objective on Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a research report on Tuesday, April 16th. Finally, Mizuho decreased their price objective on Xencor from $59.00 to $50.00 and set a “buy” rating for the company in a report on Monday, January 22nd.

Insider Transactions at Xencor

In related news, VP John R. Desjarlais sold 54,108 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total transaction of $1,048,613.04. Following the completion of the transaction, the vice president now owns 161,675 shares of the company’s stock, valued at $3,133,261.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Xencor news, CEO Bassil I. Dahiyat sold 2,741 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $23.50, for a total value of $64,413.50. Following the transaction, the chief executive officer now owns 351,894 shares of the company’s stock, valued at $8,269,509. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP John R. Desjarlais sold 54,108 shares of the stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $19.38, for a total value of $1,048,613.04. Following the sale, the vice president now owns 161,675 shares of the company’s stock, valued at approximately $3,133,261.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 101,351 shares of company stock valued at $2,152,417. Corporate insiders own 4.97% of the company’s stock.

Hedge Funds Weigh In On Xencor

A number of hedge funds have recently modified their holdings of XNCR. abrdn plc acquired a new position in shares of Xencor in the 4th quarter valued at $3,726,000. State of New Jersey Common Pension Fund D lifted its stake in Xencor by 24.8% during the third quarter. State of New Jersey Common Pension Fund D now owns 110,353 shares of the biopharmaceutical company’s stock valued at $2,224,000 after buying an additional 21,946 shares in the last quarter. Hudson Bay Capital Management LP lifted its stake in Xencor by 144.7% during the third quarter. Hudson Bay Capital Management LP now owns 232,500 shares of the biopharmaceutical company’s stock valued at $4,685,000 after buying an additional 137,500 shares in the last quarter. Deutsche Bank AG boosted its holdings in shares of Xencor by 13.0% in the third quarter. Deutsche Bank AG now owns 33,098 shares of the biopharmaceutical company’s stock worth $667,000 after buying an additional 3,805 shares during the period. Finally, Diversified Trust Co purchased a new position in shares of Xencor in the fourth quarter worth approximately $265,000.

Xencor Stock Performance

Shares of XNCR stock opened at $24.11 on Friday. The company has a market cap of $1.49 billion, a P/E ratio of -11.48 and a beta of 0.77. The business has a 50 day moving average of $21.88 and a two-hundred day moving average of $20.47. Xencor has a 52 week low of $16.49 and a 52 week high of $28.96. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 0.02.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.67). The company had revenue of $44.70 million for the quarter, compared to analyst estimates of $77.63 million. Xencor had a negative net margin of 74.90% and a negative return on equity of 18.67%. The company’s revenue for the quarter was up 106.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.20) EPS. As a group, analysts anticipate that Xencor will post -3.25 EPS for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.